Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
ImCheck Therapeutics is a biotechnology company at the forefront of immuno-oncology, designing and developing a new generation of immunotherapeutic antibodies. Their pioneering approach targets butyrophilins, a novel super-family of immunomodulators, to unleash the therapeutic potential of gamma-delta (γδ) T cells and other immune cells. ImCheck's pipeline includes first-in-class antibodies and fusion proteins aimed at treating various forms of cancer and autoimmune diseases, with lead candidates progressing through clinical trials.
Primary hub for research and development (R&D), corporate operations, and strategic management, focused on advancing their pipeline of immuno-oncology therapies targeting butyrophilins and γδ T cells.
Located within Parc Scientifique de Luminy, a major French science and technology park in Marseille, offering modern laboratory and office facilities. Proximity to leading academic research institutions and a vibrant biotech ecosystem.
A dynamic, science-driven, and collaborative environment focused on innovation in immunotherapy. Emphasizes teamwork, scientific rigor, and translating cutting-edge research into clinical solutions for patients.
Strategic location in Marseille, a key French biotech hub, provides access to specialized talent, research collaborations, and a supportive infrastructure for life sciences innovation. Serves as the central node for global operations.
ImCheck Therapeutics supports its global clinical trials, research collaborations, and business development activities from its headquarters in France and through its clinical operations presence in the United States (Cambridge, MA). This dual presence allows them to effectively manage international studies and engage with key stakeholders in both Europe and North America.
Parc Scientifique de Luminy, Biotech III – Zone Entreprises, 163 Avenue de Luminy
Marseille
Provence-Alpes-Côte d'Azur
France
Address: Clinical operations office in Cambridge, MA (Specific address not publicly listed, likely flexible or shared office space).
To facilitate the advancement of ImCheck's clinical pipeline in North America, engage with the vibrant US biotech ecosystem, and support interactions with regulatory bodies like the FDA.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, ImCheck Therapeutics' leadership includes:
ImCheck Therapeutics has been backed by several prominent investors over the years, including:
ImCheck Therapeutics has seen limited C-suite changes in the past 12 months, with one notable departure in a key development leadership role. The core executive team leading strategy, finance, medical, and scientific operations has remained stable.
Discover the tools ImCheck Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
ImCheck Therapeutics commonly uses an email format consisting of the employee's first initial followed by their last name, then '@imcheck.com'. Variations might exist but this is a frequently observed pattern.
[first_initial][last]@imcheck.com
Format
pdepenoux@imcheck.com
Example
75%
Success rate
Business Wire • May 2, 2024
ImCheck Therapeutics has initiated dosing in its EVICTION-2 Phase 2a clinical trial, evaluating its lead candidate ICT01 in combination with pembrolizumab for treating patients with platinum-resistant/refractory urothelial carcinoma (bladder cancer)....more
ImCheck Therapeutics Website • April 8, 2024
ImCheck Therapeutics presented promising preclinical data for its CD39-targeting immunocytokine ICT04 and outlined the clinical trial design for ICT01 in Acute Myeloid Leukemia (AML) at the American Association for Cancer Research (AACR) Annual Meeting 2024....more
ImCheck Therapeutics Website • January 18, 2024
ImCheck Therapeutics announced its participation and presentations at several key investor conferences in January 2024, highlighting its pipeline progress and corporate strategy to the investment community....more
ImCheck Therapeutics Website • December 12, 2023
ImCheck Therapeutics announced its upcoming presentations at the 65th American Society of Hematology (ASH) Annual Meeting, showcasing data related to its hematological malignancy programs....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including ImCheck Therapeutics, are just a search away.